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Abstract
Erythropoietin-releasing neural precursor cells (Er-NPCs) are a subclass of subventricular zone-derived neural progenitors,
capable of surviving for 6 hr after death of donor. They present higher neural differentiation. Here, Er-NPCs were studied in
animal model of Parkinson’s disease. Dopaminergic degeneration was caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
intraperitoneal administration in C57BL/6 mice. The loss of function was evaluated by specific behavioral tests. Er-NPCs
(2.5 105) expressing the green fluorescent protein were administered by stereotaxic injection unilaterally in the left
striatum. At the end of observational research period (2 weeks), most of the transplanted Er-NPCs were located in the
striatum, while several had migrated ventrally and caudally from the injection site, up to ipsilateral and contralateral sub-
stantia nigra. Most of transplanted cells had differentiated into dopaminergic, cholinergic, or GABAergic neurons. Er-NPCs
administration also promoted a rapid functional improvement that was already evident at the third day after cells adminis-
tration. This was accompanied by enhanced survival of nigral neurons. These effects were likely promoted by Er-NPCs-
released erythropoietin (EPO), since the injection of Er-NPCs in association with anti-EPO or anti-EPOR antibodies had
completely neutralized the recovery of function. In addition, intrastriatal administration of recombinant EPO mimics the
effects of Er-NPCs. We suggest that Er-NPCs, and cells with similar properties, may represent good candidates for cellular
therapy in neurodegenerative disorders of this kind.
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Introduction
Restorative therapies based on neural cell replacement
have been extensively studied, and in particular, it is con-
sidered of interest in conditions such as the loss of sub-
stantia nigra (SN) dopaminergic neurons in Parkinson’s
disease (PD; Barker et al., 2013; Barker, 2014).
Transplantation of dopamine-containing neurons
(Bjorklund et al., 2002; Kim et al., 2002; Yang et al.,
2008; Kriks et al., 2011) and allografts of ventral mesen-
cephalon tissue received and made synapses within the
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host brain and promoted recovery affection in animal
models of PD (Schultzberg et al., 1984; Lindvall at al.,
1990; Haque et al., 1997; Takahashi et al., 2007;
Martı`nez-Cerden˜o et al., 2010). In pioneer human clinical
trials, dopaminergic neurons transplanted into the caud-
ate putamen promoted the reinnervation of striatum,
with restored dopamine (DA) release. But the clinical
outcome had been highly variable (Barker et al., 2013;
Barker, 2014), and unfortunately a significant number
of these patients had developed quite debilitating side
effects, such as dyskinesias of orofacial muscles and
upper and lower extremities (Barker, 2014; Hallett
et al., 2014; Kefalopoulou et al., 2014; Hallett et al.,
2015). In addition, as predicted, the use of human brain
specimens gave rise to numerous ethical concerns (Barker
and de Beaufort, 2013; Barker, 2014), and the combined
result of ethical issues and severe side effects forced new
efforts toward other cellular sources, such as dopamin-
ergic neurons, obtained from induced pluripotent stem
cells through somatic cell reprogramming (Yu et al.,
2007; Wernig et al., 2008; Sundberg et al., 2013; Doi
et al., 2014).
Recently, we reported the existence of a subclass of
subventricular zone-derived neural progenitors (erythro-
poietin-releasing neural precursors cells [Er-NPCs]) sur-
viving after donor death, with differentiation dependent
upon autocrine release of erythropoietin (EPO; Marfia
et al., 2011). When Er-NPCs, formerly called PM-
NPCs, were applied intravenous after traumatic spinal
cord injury in the mouse, the treatment resulted in a
marked attenuation of secondary degeneration and neu-
roinflammation associated to a significant improvement
of hind limb function (Carelli et al., 2014, 2015). Most of
transplanted Er-NPCs had become cholinergic and
showed great morphological differentiation (Carelli
et al., 2015). Here, we explored the therapeutic potential
of Er-NPCs in a preclinical model of PD. Er-NPCs were
infused unilaterally into striatum of symptomatic and
dopamine-depleted 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP)-exposed C57BL/6 mice. We
observed that more than 75% of injected Er-NPCs were
vital and capable of migrating ventrally and caudally
throughout the striatum, and ipsilateral and contralateral
SN pars compacta (SNpc) were also reached.
Transplanted Er-NPCs differentiated morphologically
and biochemically being positive to microtubule-asso-
ciated protein 2 (MAP-2), neuronal nuclei (NeuN), and
tyrosine hydroxylase (TH). All these features and effects
are likely dependent on its own-released EPO, since all of
these were abolished by the coinjection of Er-NPCs with
anti-EPO or anti-EPO-R antibodies. Finally, we show
that Er-NPCs-treated animals improved their typical
Parkinsonism within the 3 days after cell transplantation,
and this was accompanied by significant sparing of SN
neurons.
Materials and Methods
Animals and Study Approval
For this study, we used adult C57BL/6 male mice
(Charles River, Milan, Italy), 3 to 4 months old and
weighing 20 to 24 g. The animals were kept for at least
7 days before the experiments were carried out in stand-
ard conditions (22 2C, 65% humidity, and artificial
light between 08:00 a.m. and 08:00 p.m.) with food and
water ad libitum. Moreover, mice were trained for 1 week
before the MPTP treatment, in order to educate them to
behavioral testing.
All of the procedures were performed by following
the Italian Guidelines for Laboratory Animals, which con-
form to the European Communities Directive of September
2010 (2010/63/UE), and the Review Committee of the
University of Milan approved the work.
Er-NPCs Isolation
Er-NPCs constitutively expressing green fluorescent pro-
tein (GFP) were obtained from adult C57BL/6-Tg(UBC-
GFP)30Scha/J mice weighing 25 to 30 g (Charles River)
as described earlier (Marfia et al., 2011; Carelli et al.,
2014, 2015).
Animal Treatments
Parkinsonism was induced by the intraperitoneal (IP)
administration of MPTP following the acute paradigm
with a small modification (Del Zompo et al., 1990;
Zuddas et al., 1990; Petroske et al., 2001). Briefly, mice
were administered of a double dose of MPTP hydro-
chloride: a first IP injection of MPTP (36mg/kg), and
after 7 days, the animals were subjected to a second IP
injection of MPTP (20mg/kg). To investigate the stabil-
ity of the lesion, a group of animals (CTRL, n¼ 8;
MPTP, n¼ 8) were sacrificed 3 days after the second
toxin administration (Day 10; Figure 1(a)), five animals
for each condition were used for DA and metabolites
determination (see later), and three animals for each con-
dition were used for histology studies. After 3 days from
the second MPTP injection, a group of animals were
transplanted with 5 104 cells/ml (5 ml) GFP expressing
Er-NPCs (n¼ 31), according to the following stereotaxic
coordinates in relation to bregma: 0.1mm posterior,
2.4mm mediolateral, and 3.6mm dorsal at the level of
left striatum (Cui et al., 2010). Two weeks after trans-
plantation (Day 24; Figure 1(a)), 13 animals from each
group (CTRL, MPTP, MPTPþEr-NPCs) were sacri-
ficed by cervical dislocation, and their brains were
removed and dissected (see Figure 1(a) for experimental
plan). Immediately after dissection, the whole striatum,
frontal cortex, and midbrain were frozen on dry ice for
neurotransmitters determination (see as follows). Twelve
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animals for each of the groups CTRL, MPTP, and
MPTPþEr-NPCs and nine animals for the group
MPTPþEr-NPCsþ anti-EPO were anesthetized by an
IP injection of sodium pentobarbital (65mg/kg), perfused
through the left ventricle with 50mL of saline solution,
and fixed with 200mL of 4% paraformaldehyde in
0.1mol/L phosphate-buffered saline (PBS). Brains were
subsequently removed from the skulls and then cryopro-
tected at 4C in sucrose 300 g/L in 0.1mol/L PBS solu-
tion for further sectioning.
Figure 1. MPTP paradigm applied reduces nigrostriatal dopamine neurons and causes functional disability in mice. (a) Experimental
plan set up to investigate the effects of Er-NPCs transplanted in MPTP mouse model of Parkinson’s disease. The photo insert
shows an example of neurosphere formed by GFP-expressing-Er-NPCs. (b) Striatal coronal slices of healthy mice (CTRL) and MPTP mice
(Day 10 after the first injection of MPTP) stained with anti-TH antibody (Bars¼ 50mm). Quantification was made by ImageJ picture analysis
software. ***p< .001 versus CTRL. (c) Evaluation of functional impairment was performed by means of two different behavioral tests
(inverted and vertical grid, see Materials and Methods section for details). Data are expressed as mean SD of two independent
experiments.
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Behavioral Tests
The recovery of motor dysfunction, before and after cell
transplantation, was investigated by means of horizontal
grid test (Tillerson and Miller, 2003) and vertical grid test
(Kim et al., 2010).
Horizontal grid test. The grid apparatus was constructed
according to Tillerson and Miller (2003). The animal was
videotaped for 30 sec, and the videos were replayed for per-
centage forepaw fault analysis using a recorder with slow
motion option. The number of unsuccessful forepaw steps
divided by the total number of attempted forepaw steps was
evaluated. Before MPTP administration, mice were accli-
mated to the grid twice a day for 1 week.
Vertical grid test. The vertical grid apparatus was constructed
according to Kim et al. (2010). For this test, the mouse was
placed 3 cm from the top of the apparatus, facing upward,
and was videotaped while it turned around and climbed
down. The score reported was the time required by the
mouse to make a turn, climb down, and reach the bottom
of the grid with its forepaw within 180 sec. Before MPTP
administration, mice were acclimated to the grid twice a day
for 1 week.
Determination of DA and Metabolites
For the analysis of DA and its metabolites, the protocol
described by Vaglini et al. (2004) was used. Briefly, the
striatal tissue samples were homogenized in 600 mL ice-
cold 0.1N perchloric acid containing 10 pg/lL dihydrox-
ybenzylamine (DBA) as the internal standard; an aliquot
of homogenate was assayed for protein. The homogen-
ates were centrifuged, and the levels of monoamines and
their metabolites in the supernatant were determined by
reverse-phase high-performance liquid chromatography
coupled to an electrochemical detector. One liter of
mobile phase contained 10.35 g (75mM) sodium dihydro-
gen orthophosphate, 0.505 g (2.5mM) heptan sulfonic
acid, 25mM EDTA, 100 mL triethylamine, and 200mL
acetonitrile adjusted to a final pH of 3.00 with phosphoric
acid. A C18 inertsil ODS-3, 4.6 250mm, 5 mm, reverse-
phase column was used (Beckman, San Ramon, CA,
USA). The mobile phase (filtered and degassed) was
delivered at a flow rate of 1.2mL/min; the applied poten-
tial was set to 0.10V (Detector 1) andþ 0.30V
(Detector 2). For catecholamine assays, a standard
curve was prepared using known amounts of DA and
metabolites dissolved in 0.1N perchloric acid containing
a constant amount (10 pg/mL) of the internal standard
(DBA) used for tissue samples. The standard curve for
each compound (DA or its metabolite) was calculated
using regression analysis of the ratios of the peak areas
(compound area or DBA area) for various concentrations
of each compound recorded at the reducing electrode. An
analogous regression analysis was performed for the oxi-
dizing electrode (Vaglini et al., 2004, 2009).
Immunohistochemistry and Quantitative Analysis
Coronal sections (20 mm) of the whole brain were cut at
25C using a cryostat (Leica), and slides were collected
onto glass slides and rinsed with PBS, treated with block-
ing solution (10% NGS, 0.2% Triton X-100) by follow-
ing our previously published protocols (Carelli et al.,
2014, 2015). The following primary antibodies were
used: MAP-2 (1:300; Chemicon), NeuN (1:100;
Millipore), TH (1:500; Millipore), choline acetyltransfer-
ase (ChAT, 1:1000; Chemicon), gamma aminobutyric
acid (GABA, 1:500; Millipore), NG2 Chondroitin sulfate
proteoglycan (1:200; Millipore), nestin (1:200; Millipore),
EPO (1:200; Santa Cruz), monocytes/macrophages
(MOMA,1:25; Millipore). The following secondary anti-
bodies were used: 546 goat anti-rabbit IgG (1:200; Alexa),
546 goat anti-mouse IgG (1:200; Alexa), and 546 donkey
anti-goat IgG (1:200, Alexa). Images were acquired using
standardized confocal microscopy (Leica SP2 confocal
microscope with He or Kr and Ar lasers; Heidelberg,
Germany). The quantification of GFP-positive trans-
planted Er-NPCs expressing typical neural markers men-
tioned earlier was determined by confocal microscopy
with the overlap application. The quantification was
expressed as percentage of positive cells versus the total
number of GFP-positive Er-NPCs. Images of SN immu-
nostaining were acquired in the region corresponding to
bregma 2.80/3.52mm as indicated in the Paxinos and
Franklin’s (2001) atlas. Microphotographic digital ana-
lysis were performed by using ImageJ software (Jensen,
2013), and without considering the ventral tegmental area
(Liang et al., 2004). The quantification of the positive
pixels versus the negative background elicits an index
score that includes the contributions from fibers and
neuronal somata. The immunostaining conditions were
the same for all sections within a single brain, in that
the staining solutions were the same, as were the reaction
times in the solutions. The microscope light intensity of
the laser was the same for analyzing all given brain sec-
tions and for determining the background optical density.
RNA Extraction and Real Time-Polymerase
Chain Reaction
IL-6 mRNA analyses were performed at 7 days after
transplant (n¼ 3 mice for each group) in striatum
homogenates as described in Carelli et al., 2015. Briefly,
left and right striatum regions were dissected out rapidly,
frozen on dry ice, and stored at 80C for further
analyses. Total RNA was extracted using TRIZOL
reagent (Life Technologies) following manufacturer’s
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instructions, quantitated, and processed. Primers were
designed using Oligo Perfect Designer Software (Life
Technologies). AmpliTaq activation 95C for 10min,
polymerase chain reaction (PCR) denaturation step
95C for 15 sec, PCR annealing step 60C for 30 sec,
PCR elongation 75C for 30 sec, and 40 cycles of PCR
were performed. PCR results were normalized versus 18S.
Primer sequences were as follows:
Statistical Analysis
Statistical analyses between groups were evaluated using
GraphPad Prism 4.00 version, and data are expressed as
meanSD. Behavioral data were analyzed with a one-
way analysis of variance (ANOVA) model with time and
group (CTRL, MPTP, MPTPþEr-NPCs, MPTPþEr-
NPCsþ anti-EPO, and MPTPþEr-NPCsþ anti-EPOR)
as factors. The effects of MPTP and the various com-
bined treatments on striatal catecholamine levels were
evaluated statistically by using ANOVA with Scheffe-F
analysis. The null hypothesis was rejected when p< .05.
Markers expression data were analyzed in triplicate, and
results were expressed as the average of three animals.
The expression each marker was analyzed by one-way
ANOVA followed by Bonferroni’s multiple comparisons
test to assess statistical significance.
Results
Experimental Model
The experimental setup of this study is represented in
panel A of Figure 1. The effect of MPTP administration
on TH-positive neurons and axon terminals into the stri-
atum was evaluated 10 days after the first MPTP admin-
istration. Panel B of Figure 1 shows representative TH
immunoreactivity in striatum of controls (healthy;
CTRL) and MPTP-treated mice. As it is well known,
MPTP causes a massive loss of TH-positive cell bodies
and axons that was quantified to be over 70% (Figure
1(b)). In support of the histological data, we performed
also two behavioral tests, designed for the investigation
of the typical functional impairment occurring in
Parkinsonian animals (Figure 1(c)). The horizontal grid
test allowed the assessment of the forepaw faults in
healthy and MPTP-treated mice. The behavioral impair-
ment was already marked as early as 1 day after MPTP
administration with 73% of forepaw faults (p< .001 vs.
CTRL). Through the vertical grid test, we assessed the
time required by the mouse to turn around and descend
the grid once positioned on the top. Following MPTP
administration, mice hesitated and remained on the top
of the grid much longer, therefore the time required to
turn and descend from the top of the grid was markedly
longer than control. The behavioral impairment
remained significantly high throughout the experimental
period (Figure 1(c)). In addition to the neuropathological
changes, we observed that MPTP caused the reduction of
striatal DA and related 3,4-dihydroxyphenylacetic acid
and homovanillic acid metabolites as expected (Corsini
et al., 1985; Table 1).
Localization of Transplanted Er-NPCs
Healthy and lesioned animal brains with or without Er-
NPCs injection were sectioned. A large portion
(78.50 7.51%) of the 2.5 105 cells injected into the
left striatum of each animal was still present in the
brain within 2 weeks after transplantation. The vast
majority (69.56 4.5%) of GFP-positive transplanted
Er-NPCs were within the striatum (Figure 2(a)).
Grafted Er-NPCs appeared rather differentiated with an
oval soma and abundant neuritic processes. Previous
reports had shown that transplanted stem cells could
migrate into the host striatum (Kim et al., 2002;
Martinez-Cerden˜o et al., 2010); here, we observed that
grafted Er-NPCs migrate from the injection site across
the striatum (Figure 2(a)). In 2 weeks, Er-NPCs had
migrated up to 3100mm from the site of injection follow-
ing a ventral direction (Figure 2(a)). In our previous
work, we showed that Er-NPCs express and release
EPO that exerts an autocrine action regulating the pre-
cursor’s differentiation (Marfia et al., 2011). With the aim
at investigating the role of EPO in the precursor’s repara-
tive effect, we performed the coinjection of anti-EPO or
Table 1. Striatal Determination of Dopamine and Metabolites at
Day 10 After MPTP Administration.
Neurotransmitters
CTRL
(ng/mg of proteins)
MPTP
(ng/mg of proteins)
DA 98.61 10.70 47.58 16.20 p< .001
DOPAC 9.07 1.20 5.20 2.36 p< .001
HVA 14.65 1.83 6.86 2.13 p< .001
3-MT 6.85 1.28 6.71 0.56
Note. DA¼ dopamine; DOPAC¼ 3,4-dihydroxyphenylacetic acid;
HVA¼ homovanillic acid; 3-MT¼ 3-methoxytyramine; CTRL¼ control;
MPTP¼ 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Levels of DA,
DOPAC, HVA, and 3-MT were quantified in the striatum by using HPLC
analysis (see Materials and Methods section). Data are expressed as
mean SD (n¼ 5 mice in each group).
18S F: TTTCGGAACTGAGGCCATGATTAAG
R: AGTTTCAGCTTTGCAACCATACTCC
IL6 F: TCCAGTTGCCTTCTTGGGACTGATGCTGGT
R: AGTTTCAGATTGTTTTCTGCAAGTGCATCA
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anti-EPO receptor antibodies at the concentration of
3 mg/ml (Marfia et al., 2011). The coinjection of anti-
EPO antibody strongly reduced the dorso-ventral migra-
tion of Er-NPCs (Figure 2(a)). The graph represented in
Figure 2(b) reports the comparison of the migratory dis-
tance covered by Er-NPCs in absence or presence of anti-
EPO antibody (Figure 2(b)). The inhibition of EPO sig-
nificantly reduced the migratory ability of Er-NPCs. The
reassembly of serial pictures, obtained from longitudinal
sections, by confocal acquisitions (Figure 3(a)) shows
that Er-NPCs migrate linearly within the striatum
(Figures 2 and 3) also following a rostro-caudal pathway.
The coinjection with anti-EPO antibody abolished the
migration following such a route suggesting that it
might be somewhat regulated by EPO (Figure 3(b))
Through transversal brain sections, we observed that
the Er-NPCs migrated beyond the borders of the stri-
atum, and that SN pars compacta, ipsilateral, and contra-
lateral to the injection was reached (Figure 4(a)). Here,
Er-NPCs integrate in the SNpc among endogenous
TH-positive neurons (Figure 4(b) and (c)). By using refer-
ences available in adult mouse brain atlas (Paxinos
and Franklin 2001; Allen Mouse Brain Atlas available
online), we calculated that Er-NPCs travelled for 3280–
3360 mm following the rostro-caudal direction. The Er-
NPCs localization seemed to be restricted to the brain
areas affected by MPTP, we did not find GFP positive
Er-NPCs in other nearby regions. Very few cells were
found in the cortex probably due to spilling while low-
ering the needle into the striatum.
Expression of Typical Markers
by Transplanted Er-NPCs
Close to the injection site, a higher number of Er-NPCs
were positive to nestin (precursor cell marker), while most
of the migrated Er-NPCs resulted positively marked by
anti-NeuN and anti-MAP-2 antibodies (markers of
Figure 2. Grafted Er-NPCs migrate throughout the striatum following a dorso-ventral pathway. (a) Confocal images of Er-NPCs
intrastrial distribution (green) 2 weeks after transplantation in coronal sections taken from Er-NPCs-injected MPTP mouse brains with or
without anti-EPO antibody (Bars¼ 100mm). (b) Length of migration from the injection site of Er-NPCs in absence or presence of anti-Epo
antibody (distance expressed in mm). Images have been evaluated by confocal picture analysis software. ***p< .001 versus Er-NPCs-
transplanted mice in absence of the anti-EPO coinjection. Data refer to one brain for each experimental condition. Comparable results
have been observed on other two investigated animals for each experimental condition.
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neuronal differentiation; Figure 5(a)). Distal to the injec-
tion site, only a lower percentage of cells was positive to
NG2 (marker of oligodendrocytes precursors) and nestin.
The number of GFP-positive transplanted Er-NPCs
expressing typical neural markers was determined by con-
focal microscopy. The quantification (expressed as per-
centage of positive cells) shows that Er-NPCs, migrated
from the site of injection, were 84.50 7.97% positive for
NeuN and 61.42 8.28% for MAP-2, while
41.13 7.24% were positive for NG2 and
36.41 8.60% for Nestin (Figure 5(a)). Therefore, the
EPO-dependent Er-NPCs migration correlates with a
higher differentiation as the blockade of EPO action by
means of anti-EPO impaired also the in vivo differenti-
ation toward neuronal features (Figure 5(b) and Table 2).
We also found that a large amount of transplanted
cells located distally to the injection site, expressed a
marker related to DA synthesis, such as TH
(55.90 8.91% in 511 analyzed cells). The cholinergic
marker ChAT, which is expressed by striatal excitatory
interneurons, was found in 57.03 7.68% of the 489 ana-
lyzed cells, while a relative lower amount of cells
expressed GABA (25.7 5.38% in 354 analyzed cells;
Figure 6). Anti-EPO antibody strongly blocked also the
expression of specific neurotransmitter markers, less than
20% of Er-NPCs resulted positively stained for TH, and
the expression of ChAT was decreased significantly to
less than 3% (Figure 6 and Table 3).
Grafted Neural Precursors Express EPO and
Regulate EPO Expression in the Recipient Striatum
The Er-NPCs expression of EPO after the transplant was
investigated by immunofluorescence in coronal section of
striatum 2 weeks postinjection. Figure 7 shows that the
great majority of transplanted Er-NPCs are positive to
the staining for EPO. Although when Er-NPCs were
coinjected with the anti-EPO antibody, the EPO expres-
sion resulted completely abrogated (Figure 7). Moreover,
it is appreciable to note that Er-NPCs injected with anti-
Epo antibody maintain an immature round morphology
(Figure 7). However, EPO is expressed also in the host
central nervous system where, according to our previous
reports (Digicaylioglu et al., 1995; Carelli et al., 2016), it
exerts neurotrophic and neuroprotective actions (Konishi
et al., 1993; Digicaylioglu et al., 1995; Gorio et al., 2002;
Figure 3. Injected Er-NPCs migrate rostro-caudally throughout the striatum. (a) Sagittal sections of Er-NPCs-injected MPTP mouse
brain. Transplanted Er-NPCs (green) migrate for several microns into the striatum following rostro-caudal directions (Bars¼ 100 mm). The
same results have been observed on other two investigated animals with similar approach. (b) Quantification of rostro-caudal length
pathway of Er-NPCs injected in absence or presence of anti-EPO antibody. ***p< .001 versus Er-NPCs-transplanted mice. Data refer to
one brain for each experimental condition. Comparable results have been observed on other two investigated animals for each experi-
mental condition.
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Marti, 2004; Jelkmann, 2011). The expression of EPO
was then investigated by immunofluorescence in the stri-
atum of MPTP animals, and in MPTP animals treated
with Er-NPCs coinjected or not with anti-EPO antibody.
To perform this analysis, striatum tissue sections were
taken from areas neighboring the localization of the
transplanted cells. The immune-reactivity was abundant
in the striatum of healthy control animals (CTRL;
Figure 8). The EPO expression resulted strongly abro-
gated in the degenerated striatum (MPTP; Figure 8),
while its expression resulted completely preserved by the
injection of Er-NPCs and, again, seemed strictly related
to their physiologic capability to produce erythropietin
(MPTPþEr-NPCs), as the coinjection of anti-EPO
antibody strongly abolished the expression of EPO
(MPTPþEr-NPCsþ anti-EPO; Figure 8).
Er-NPCs Transplantation Promotes Recovery of
Function and Preserve TH Immunoreactivity in SN
The therapeutic effect of intrastriatal injection of Er-
NPCs was investigated also by evaluating the functional
recovery by means of behavioral tests described earlier
(see Figure 1(c) and Materials and Methods section).
Three days after cell injection, the percentage of forepaw
faults of Er-NPCs-injected mice was 34.26 7.8% (hori-
zontal grid test) compared with 89.3 2.6% of not-trea-
ted MPTP animals (Figure 9(a)). The early improvement
Figure 4. Injected Er-NPCs reach the substantia nigra. (a) Schematic representation of mouse brain transversal section with images
representing the distribution of Er-NPCs (green) 2 weeks after transplantation (Day 24 in Figure 1(a)). Er-NPCs migrate rostro-caudally for
more than 3 mm reaching the substantia nigra. (b) and (c) Magnification of brain coronal sections obtained from Er-NPCs-injected MPTP
mice immunostained with anti-NeuN or anti-TH (red), GFP is showed in green, and nuclei were stained with DAPI (blue; Bars¼ 100mm for
TH; 50 mm for NeuN). Images are representative of (n¼ 3) investigated brains. CuPu¼ caudate putamen; ST¼ subthalamus;
SNpc¼ substantia nigra pars compacta.
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Figure 5. Most Er-NPCs adopted a neuronal fate when transplanted into striatum of MPTP mice. (a) Striatal coronal sections relative to
Er-NPCs-transplanted MPTP mice. (b) Striatal coronal sections of Er-NPCs-transplanted MPTP mice in presence of the coinjection of anti-
EPO antibody. Sections were immunostained with neural differentiation specific markers (MAP-2, NeuN, NG2, and nestin). The immu-
nostaining is showed in red. Er-NPCs are showed in green (GFP). Nuclei are stained in blue (DAPI). Scale bars represent 50 mm for Nestin,
Map-2, and NG2 in panel A. For all other images, bars represent 100 mm. Analysis was performed 2 weeks after Er-NPCs injection. Graphs
report the percentage of GFP-positive cells expressing investigated markers in nine different fields for each condition (n¼ 3 mice each
group; 3 fields or mouse). Data are expressed as mean SD. *p< .05 versus NeuN injection site.
Table 2. Neural Specific Markers Expression by Er-NPCs Migrating Throughout the Striatum of MPTP Mice.
Injection site Migration
Er-NPCs
(%)
Er-NPCsþ anti-EPO
(%)
Er-NPCs
(%)
Er-NPCsþ anti-EPO
(%)
Nestin 63.16 9.30 97.79 1.27
(p< .001 vs. Er-NPCs)
36.41 5.60 90.86 2.70
(p< .001 vs. Er-NPCs)
MAP-2 39.33 0.17 30.28 0.79 61.42 3.28 50.31 6.42
NG2 36.69 6.19 43.41 2.32 41.13 7.24 47.59 4.85
NeuN 38.88 17.57 22.91 7.65 84.50 7.97 19.17 3.06
(p< .001 vs. Er-NPCs)
Note. MAP-2¼microtubule-associated protein 2; NeuN¼ neuronal nuclei; Er-NPCs¼ erythropoietin-releasing neural precur-
sors; EPO¼ erythropoietin. The comparison refers to Er-NPCs injected alone or in presence of anti-EPO antibody.
Quantification of positive cells was made by ImageJ picture analysis software. Data are expressed as mean of three different
fields for each condition SD.
Carelli et al. 9
observed in Er-NPCs-transplanted mice was then main-
tained throughout the period of observation, while
MPTP mice gradually worsened, reaching the maximum
deficit at Day 8 (Figure 9(a)). The difference between
Er-NPCs-treated and MPTP groups was even more con-
spicuous, when their motor coordination ability was eval-
uated by means of the vertical grid test. Three days after
transplantation, Er-NPCs-injected animals showed a sig-
nificant improvement in the time required for turning and
descending the grid (62.7 8.4 sec). While the time
employed by MPTP mice was almost twice as long
(112.7 2.7 sec). The functional improvement promoted
by Er-NPCs treatment steadily increased reaching values
similar to controls (healthy mice) within 2 weeks after
cells injection (Figure 9(a)). Er-NPCs inoculation was
Figure 6. Most Er-NPCs express neuronal lineage markers after transplantation into the striatum of MPTP mice. Confocal images
of coronal striatum sections of MPTP mice treated with Er-NPCs (green; GFP) (a) and Er-NPCsþ anti-EPO antibody (b). Slices were
immunodecorated with anti-TH (TH; red), anti- Choline Acetyltransferase (ChAT; Red), and anti-gamma-aminobutyric acid (GABA; red).
Nuclei are stained in blue (DAPI). Scale bars represent 100 mm for the first lane and 50mm for the second lane. Graphs report the
percentage of GFP-positive cells expressing investigated markers in nine different fields for each condition (n¼ 3 mice each group; 3 fields
or mouse). Data are expressed as mean SD.
Table 3. Percentage of Er-NPCs Positive to TH, ChAT, and
GABA.
Markers
Er-NPCs
(%)
Er-NPCsþ anti-EPO
(%)
TH 55.90 8.91 13.80 7.35
p< .001
ChAT 57.00 7.68 2.52 2.56
p< .001
GABA 25.70 5.38 22.90 3.22
Note. TH¼ tyrosine hydroxylase; ChAT¼ choline acetyltransferase;
GABA¼ gamma aminobutyric acid; Er-NPCs¼ erythropoietin-releasing
neural precursors; EPO¼ erythropoietin. The comparison refers to Er-
NPCs injected alone or in presence of anti-EPO antibody. Quantification
of positive cells was made by ImageJ picture analysis software. Data are
expressed as mean of three different fields for each condition SD.
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performed with coadministration of anti-EPO or anti-
EPOR. Data show that the addition of either antibodies
obliterated the positive effect of Er-NPCs administration
described earlier (Figure 9(a)). Such a counteractive effect
was observed with both behavioral motor tests. The
administration of recombinant human-EPO (rhEPO;
1U/g) in MPTP mice significantly improved the behav-
ioral impairment as early as 3 days after injection in both
tests, as Er-NPCs did (Figure 9(a)). The injection of anti-
EPO and anti-EPOR antibodies alone did not modify the
animal behavioral impairment caused by MPTP
(Supplemental Table 1). These data suggest that the posi-
tive action of Er-NPCs in MPTP mice was likely due to
EPO release by transplanted Er-NPCs. Moreover, the
positive outcome due to Er-NPCs injection is stable for
a long observational research period; so far, we moni-
tored the functional recovery up to 50 days after
Er-NPCs transplantation (Supplementary Figure 1).
The histological analysis performed by immunofluor-
escence 2 weeks after transplantation shows that
TH-positive cell bodies of the SN were very faintly detect-
able in MPTP mice, as expected (Figure 9(b) and (c)).
The TH immunoreactivity was significantly higher after
Er-NPCs transplantation (Figure 9(b) and (c)), and in the
SN of anti-EPO coinjected mice, the TH immunoreactiv-
ity was comparable to MPTP group (Figure 9(b) and (c)).
Tissue levels of DA and its metabolites were
determined by high-performance liquid chromatography
(see Materials and Methods section). MPTP exposure
caused a 50% reduction of DA in both the left and
right striatum that was maintained up to the end
of experimentation period (24 days after first MPTP
administration; Table 4). Such a loss was not modified
by Er-NPCs transplantation (Table 4). Therefore, the
behavioral recovery promoted by Er-NPCs occurs in
absence of any restoration of DA, 3,4-dihydroxypheny-
lacetic acid, homovanillic acid, and 3-methoxytyramine
that remained reduced and unaffected by the treatment
with Er-NPCs (Table 4). Levels of NE, 5-HT, and 5-HIAA
were also measured. In control healthy animals (CTRL),
Figure 7. Grafted Er-NPCs express EPO after transplantation. (a) Expression of EPO was investigated by immunofluorescence in striatal
coronal sections MPTP animals injected with Er-NPCs in absence or presence of anti-EPO antibody. Analysis was performed 2 weeks after
Er-NPCs injection. Er-NPCs are showed in green (GFP), and EPO staining is showed in red, (Bars¼ 50mm). (b) The percentage of GFP-cells
expressing EPO is reported in the graph. Data are expressed as mean of the quantification performed in three different fields for each
condition SD. ***p< .001.
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the striatal levels of these neurotransmitters were as fol-
lows: 8.74 1.25ng/mg proteins (NE), 24.02 1.55ng/mg
proteins (5-HT), and 7.87 0.37 (5-HIAA), respectively
(Supplementary Table 2). Such levels were not affected
neither by MPTP administration nor by the injection of
Er-NPCs (Supplementary Table 2). Neurotransmitters
were also quantitatively determined in frontal cortex and
midbrain homogenates obtained from healthy (CTRL),
MPTP, and MPTPþEr-NPCs animal groups, no
significant differences were found among these groups
(data not shown).
Er-NPCs Transplantation Down-Regulate IL-6 mRNA
Levels and Macrophages Invasion of the Striatum
Inflammation is part of the physiological response to
MPTP as indicated by astroglia activation (Gao et al.,
2003; Wirdefeldt et al., 2011). To investigate the
Figure 8. Er-NPCs injection preserves the EPO immunoreactivity in the striatum of MPTP animals. (a) Representative confocal images of
striatal slices immunostained with EPO. Slices were obtained from brains of healthy mice (CTRL), mice injected with MPTP without cell
treatment (MPTP) or treated with Er-NPCs injected alone (MPTPþ Er-NPCs) or in presence of anti-EPO antibody (MPTPþ Er-
NPCsþ anti-EPO). Scale bars represent 50 mm in the first lane and 20 mm in the second lane. (b) The graph reports the quantification of EPO
fluorescence intensity made by ImageJ picture analysis software. For the groups MPTPþ Er-NPCs and MPTPþ Er-NPCsþ anti-EPO, slices
were chosen from striatal areas where injected Er-NPCs were absent. The analysis was performed by evaluating nine different fields for each
condition (n¼ 3 mice each group; 3 fields or mouse). ***p< .001 versus CTRL, ###p< .001 versus anti-EPO, p< .001 versus MPTP.
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Er-NPCs anti-inflammatory action, levels of IL-6 mRNA
and monocytes/macrophages invasion were evaluated in
both left and right striatum. The graph reported in panel
A of Figure 10 shows a significant counteraction of IL-6
increase in the left striatum of Er-NPCs-treated MPTP
mice (Figure 10(a)). Such effect was less marked in the
right striatum (contralateral to the transplant). In add-
ition, the striatal invasion by macrophages, evaluated by
Figure 9. EPO released by transplanted Er-NPCs promotes their therapeutic effect. (a) Horizontal and vertical grid tests show the
recovery of function in MPTP-intoxicated animals transplanted with Er-NPCs. Other groups of MPTP animals received specific antibodies
against EPO (anti-EPO) and EPO receptor (anti-EPO R) in addition to Er-NPCs. rhEPO (1 U/g) was administered via the same route as
positive control. Data are expressed as mean of three different experiments SD (n¼ 3 animals for each group in each experiment).
Statistical differences were determined by means of one-way ANOVA test followed by Bonferroni posttest. p< .001, p< .01 versus
CTRL, ***p< .001 versus MPTP. (b) Representative TH staining of midbrain coronal sections of not-treated MPTP mice and MPTP mice
grafted with Er-NPCs in presence or not of anti-EPO antibody. TH staining is showed in red and nuclei in blue (DAPI). Scale bars represent
50 mm. The graph reports the quantification of fluorescence intensity obtained by ImageJ picture analysis software. (c) The analysis was
performed by evaluating nine different fields for each condition (n¼ 3 mice each group; 3 fields or mouse). *p< .05 versus CTRL and
#p< .05 versus MPTP.
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staining with anti-MOMA (monocytes/macrophages) in
both left and right striatum, was counteracted by Er-
NPCs transplantation (Figure 10(b)).
Discussion
This study was aimed at evaluating the fate and effects of
transplanted EPO-releasing neural precursors (Er-NPCs)
in the MPTP experimental mouse model of PD. Here, we
report that, 2 weeks after transplantation, Er-NPCs are
differentiating with expression of neural markers and
migrate from the injection site throughout the striatum
by following dorso-ventral and rostro-caudal pathways
to reach ipsilateral and contralateral SNpc. In addition,
such a single administration of Er-NPCs improves the
motor deficits evaluated by horizontal and vertical grid
tests. All of the described features depend on autocrine
EPO production and release by Er-NPCs, as their co-
injection with anti-EPO or anti-EPO receptor antibodies
abrogates these favorable effects.
Er-NPCs are adult neural stem cells isolated from sub-
ventricular zone 6 hr after death of the mouse donor
(Marfia et al., 2011). These cells, when infused in tail
vein, after experimental traumatic spinal cord injury
migrate to lesion site, attenuate secondary degeneration,
and significantly ameliorate recovery of function (Carelli
et al., 2014, 2015). In addition, Er-NPCs survive and
could be found even long time (90 days) after transplant-
ation in such a strongly unfavorable environment; where
they differentiate into cholinergic neuronal-like cells and
counteract posttraumatic neuroinflammation (Carelli
et al., 2014, 2015).
So far, fetal tissue transplantation procedures are the
most studied stem cells transplantation approach to cure
PD (Tsui and Isacson, 2001; Barker et al., 2013; Barker,
2014). Despite the wake of a long series of encouraging
open-label studies, the initial enthusiasm for such pro-
cedures almost vanished when two double-blind
placebo-controlled clinical trials showed only moderate
symptomatic improvements that were accompanied by
severe disabling dyskinesias (Tsui and Isacson, 2001;
Barker, 2014). To overcome such negative outcomes,
recent work has been centered on the generation of TH-
positive neurons from ESCs (Ortiz et al., 2007; Cai et al.,
2009), embryonic neural stem cells, mesenchymal stroma
cells, and more recently pluripotent stem cells, in order to
be applied in experimental models of PD (Kim et al.,
2002; Barzilay et al., 2009; Friling et al., 2009; Hallett
et al., 2015; Pollock et al., 2016).
Here, we describe that, after intrastriatal injection,
more than 75% of Er-NPCs survive, integrate into the
striatum, reach a mature morphological phenotype, and
differentiate mostly in neuronal-like cells. Such differen-
tiation is higher for those cells that migrate to more distal
sites from the injection point: 60% MAP-2 positive and
above than 80% NeuN-positive. Most of Er-NPCs differ-
entiated in TH positive cells, and a large percentage of
these were positive for ChAT and GABA. Er-NPCs
Table 4. Er-NPCs Injection Did Not Promote the Increase of DA and its Metabolites.
Right striatum CTRL MPTP MPTPþ Er-NPCs
DA 99.52 11.32 48.28 19.50
p< .001 versus CTRL
36.25 11.07
p< .001 versus CTRL
DOPAC 8.57 1.00 4.61 2.36
p< .001 versus CTRL
3.90 1.06
p< .001 versus CTRL
HVA 15.56 2.02 7.68 2.24
p< .001 versus CTRL
8.28 1.84
p< .001 versus CTRL
3-MT 7.75 1.18 6.71 0.56 6.71 2.10
Left striatum
DA 99.52 11.30 54.44 4.65
p< .001 versus CTRL
32.32 8.61
p< .001 versus CTRL
DOPAC 8.57 1.00 6.09 1.06
p< .001 versus CTRL
5.27 1.13
p< .001 versus CTRL
HVA 15.56 2.02 13.33 3.03
p< .001 versus CTRL
10.03 2.56
p< .001 versus CTRL
3-MT 7.75 1.18 8.95 1.62 6.15 1.93
Note. DA¼ dopamine; DOPAC¼ 3,4-dihydroxyphenylacetic acid; HVA¼ homovanillic acid; 3-MT¼
3-methoxytyramine; CTRL¼ control; MPTP¼ 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Er-
NPCs¼ erythropoietin-releasing neural precursors. The determination was performed at 15 days
after cells transplantation by HPLC (see Materials and Methods section). Levels of DA, DOPAC,
HVA, and 3-MT were determined separately in the left (ipsilateral to the injection) and right (contra-
lateral to the injection site) striatum. Data are expressed in ng/mg of proteins as mean of two
experiments SD (n¼ 5 mice in each group).
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remaining in the area of injection show a round morph-
ology accompanied by the nestin expression. Differently
from what had been previously observed, with the trans-
plantation of embryonic MGE precursors cells into adult
rat striatum (Martinez-Cerdeno et al., 2010), the migra-
tory pathways of Er-NPCs seem to be defined by follow-
ing a linear route, as these cells did not spread in other
parts within the striatum. Moreover, Er-NPCs had
migrated across the striatum and reached the SN where
they integrate. It therefore appears that some specific sig-
nals capable of directing the cellular migratory process
must exist and this seemed in strict relation to the release
of EPO by Er-NPCs. The EPO neuroprotective and anti-
inflammatory effects are very well known and supported
by a large body of literature, showing that in vivo
administration of EPO promotes recovery of function
after central nervous system lesions (Gorio et al., 2002;
Brines and Cerami, 2008). Also in rat models of PD, it
has been shown that the administration of rhEPO or EPO
analogs had neuroprotective and neuro-rescue effects
(Thomas et al., 2013; Jia et al., 2014; Erbas et al.,
2015). Therefore, it is conceivable that the release of
such a neuroprotective factor by Er-NPCs may also
have a favorable impact on the striatum dopaminergic
functions, and consequently, on behavioral recovery.
Ten days after MPTP administration, before the injection
of Er-NPCs, mice showed important behavioral deficits
that were quickly reverted by Er-NPCs transplantation.
At Day 8 after Er-NPCs injection, the behavioral param-
eters were comparable to that of healthy control animals.
Such a recovery was independent from any improvement
in striatal DA content, since the loss, caused by MPTP,
remained unaltered after transplantation of Er-NPCs. It
is therefore clear that the protective or reparative action
of Er-NPCs is not mediated by the recovery of DA levels
in the striatum, but likely by an improved efficacy of the
remaining DA in the striatum under the trophic action of
Er-NPCs-released factors such as EPO. These may lead
to an enhanced efficacy of the synaptic dopaminergic
transmission by an action exerted on striatal and SN
microenvironment favoring the survival of dopaminergic
cell bodies and striatal axon terminals. It is conceivable
that the suppression of the MPTP-mediated inflamma-
tion may have increased the efficacy of the remaining
DA (Hantraye et al., 1992). Indeed, a preservation of
TH labeling can be observed in both brain areas, and
this is accompanied by a strong preservation of EPO
expression in the striatum of grafted animals. It should
also be noted that Er-NPCs migrate to SN ipsilateral and
contralateral to the injection site, and this may have
affected SN neuroinflammation.
Since Er-NPCs-mediated behavioral recovery was pre-
vented by the intrastriatal blockade of EPO or EPOR,
and that the direct EPO-administration into MPTP
affected striatum promoted a prompt behavioral recov-
ery, we believe that EPO may be one of the effector of
Er-NPCs transplants. This may modify the striatal micro-
environment thanks to a dual effect. First, due to the
modulation of the migratory response by endogenous
stem cells toward the area of Er-NPCs accumulation.
EPO has been shown to direct the migration of endogen-
ous stem cells toward EPO-reach source (Shingo et al.,
2000; Erbas et al., 2015). Second, the mechanism could be
related to a local counteraction of inflammation and neu-
roprotective action (Agnello et al., 2002; Gorio et al., 2002;
Chen et al., 2007) on neurons and neural
processes affected by MPTP. The results of such actions
may be the reexpression of TH by MPTP-lesioned SN
neurons. A similar effect was observed after a septo-
hippocampal lesion, where septal neurons recovered
Figure 10. Er-NPCs transplantation down-regulates IL-6 mRNA
levels and reduces macrophages invasion. (a) Expression of IL-6
mRNA levels was evaluated by real time RT-PCR. Each group was
composed of three mice. Values represent the number of fold
increase versus control and is reported as mean SD. *p< .05
versus CTRL, **p< .01 versus CTRL, and p< .05 versus MPTP.
(b) The graph reports the quantification of MOMA (mouse
monocytes/macrophages marker) positive cells performed in stri-
atal coronal slices of healthy (CTRL) mouse brain, MPTP mouse
brain, and MPTP mouse brain injected with Er-NPCs (MPTPþ
Er-NPCs). The analysis was performed by evaluating three different
fields for each condition. Date are reported as mean SD. **p< .01
versus CTRL, p< .01 versus MPTP, $$p< .01 versus
contralateral.
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ChAT positivity following NGF or BDNF infusion
(Morse et al., 1993). Our previous work in experimental
traumatic spinal cord injury reported the reduction of
inflammatory cytokines levels, reactive GFAP-positive
gliosis, and macrophage infiltration after the treatment
with rhEPO (Gorio et al., 2002) or administration of
Er-NPCs (Carelli et al., 2014, 2015). This seems to
happen also in the present work by the counteraction of
inflammation events caused by MPTP, particularly ipsi-
lateral to the injection site. These counteractive effects on
astrocytes are quite relevant, since these cells are posi-
tively activated in PD and produce an elevated level of
inflammatory cytokines and reactive oxygen species
(Block and Hong, 2007). Moreover, such an activation
is correlated with increased neural death (McGeer et al.,
1988; Sofroniew, 2005). Future studies will be needed to
understand in deep the physiological integration of Er-
NPCs after transplantation into the adult striatum. Our
previous work performed in vitro showed that Er-NPCs
are able to differentiate in GFAP-positive cells (Marfia
et al., 2011). However, in vivo, after transplantation in
experimental model of traumatic spinal cord injury, Er-
NPCs differentiated mostly in neurons and did not show
GFAP positivity (Carelli et al., 2015). For the future,
further experiments need to be done to investigate
whether transplanted Er-NPCs in PD experimental
models could differentiate into astrocytes or play any
role in striatal astrogliosis.
Conclusions
Er-NPCs markedly improve morphological, biochemical,
and behavioral dysfunctions caused by MPTP intoxica-
tion. This effect is likely mediated by local EPO release,
which is also effective when applied directly, and the miti-
gation of the neuro-inflammatory events may be the key
factor for achieving recovery of function. Therefore,
transplantable cells capable of releasing anti-inflamma-
tory, neuroprotective, and neurothrophic factors may
represent a promising path for the treatment of neurode-
generative disorders (Pollock et al., 2016), and in this
specific case, EPO may be effective.
Summary
Neural precursors naturally releasing EPO were applied
to an MPTP-induced mouse model of Parkinson’s dis-
ease. These cells differentiated and migrated in the
brain areas affected by the disease and promoted recovery
of function.
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